A Retrospective Study on the Diagnostic Value of Serum miR-206 in Rhabdomyosarcoma

Children's Oncology Group0 sites40 target enrollmentSeptember 2011

ConditionsSarcoma

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Sarcoma
Sponsor: Children's Oncology Group
Enrollment: 40
Primary Endpoint: Serum miR-206 as a biomarker for RMS
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in samples from patients with rhabdomyosarcoma.

Detailed Description

OBJECTIVES: * Determine whether circulating muscle-specific microRNAs, especially serum miR-206, are potential biomarkers for rhabdomyosarcoma (RMS). OUTLINE: Archived serum samples are analyzed for miR-206 expression. PROJECTED ACCRUAL: A total of 15 samples from patients with alveolar rhabdomyosarcoma (RMS), 15 from patients with embryonal RMS, and 10 from patients without RMS will be accrued for this study.

Registry

clinicaltrials.gov

Start Date

September 2011

End Date

May 2016

Last Updated

9 years ago

Study Type

Observational

Sex

All